A LinkedIn post from Flatiron Health highlights the company’s focus on using real-world evidence to understand longitudinal patient journeys across diverse markets. The post describes a shift in evidence generation, emphasizing that connected data, rather than volume alone, is central to deriving actionable insights on treatment outcomes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, advances in artificial intelligence and large language models are increasing the scale of data that can be analyzed while reducing time to insight. This is portrayed as moving real-world evidence from a complementary role to a more foundational component of clinical and market decision-making.
The post points to Flatiron’s prostate Panoramic dataset, covering nearly 400,000 patients across Germany, the U.K., and the U.S., built on a common data model to enable interoperability and global insights. It notes that this dataset is being used to address gaps in areas such as BRCA testing, HRR mutation outcomes, and treatment sequencing, which may influence how care pathways are designed.
For investors, the content suggests Flatiron is investing in scalable, AI-enabled data infrastructure with international reach, which could strengthen its competitive position in oncology data and analytics. If these capabilities translate into differentiated real-world evidence offerings for biopharma, providers, and payers, they may support higher-value contracts, deeper customer integration, and long-term revenue visibility in the evidence generation market.